Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 5
1984 2
1985 16
1986 17
1987 14
1988 27
1989 19
1990 28
1991 25
1992 28
1993 19
1994 24
1995 28
1996 25
1997 28
1998 25
1999 26
2000 30
2001 24
2002 26
2003 20
2004 24
2005 18
2006 30
2007 40
2008 32
2009 28
2010 24
2011 39
2012 29
2013 31
2014 32
2015 44
2016 38
2017 35
2018 40
2019 30
2020 16
2021 19
2022 24
2023 16
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

971 results

Results by year

Filters applied: . Clear all
Page 1
Esmolol to Treat the Hemodynamic Effects of Septic Shock: A Randomized Controlled Trial.
Cocchi MN, Dargin J, Chase M, Patel PV, Grossestreuer A, Balaji L, Liu X, Moskowitz A, Berg K, Donnino MW. Cocchi MN, et al. Shock. 2022 Apr 1;57(4):508-517. doi: 10.1097/SHK.0000000000001905. Shock. 2022. PMID: 35066509 Free PMC article. Clinical Trial.
There was no difference in number of shock free days between the esmolol (2, IQR 0, 5) and control groups (2.5, IQR 0, 6) (P = 0.32). ...Esmolol was associated with decreased levels of C-reactive protein over 24 h. ...
There was no difference in number of shock free days between the esmolol (2, IQR 0, 5) and control groups (2.5, IQR 0, 6) (P = 0.32). …
Esmolol.
O'Flaherty D. O'Flaherty D. Can J Anaesth. 1993 Jul;40(7):687-8. doi: 10.1007/BF03009720. Can J Anaesth. 1993. PMID: 8104725 No abstract available.
Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial.
Morelli A, Ertmer C, Westphal M, Rehberg S, Kampmeier T, Ligges S, Orecchioni A, D'Egidio A, D'Ippoliti F, Raffone C, Venditti M, Guarracino F, Girardis M, Tritapepe L, Pietropaoli P, Mebazaa A, Singer M. Morelli A, et al. JAMA. 2013 Oct 23;310(16):1683-91. doi: 10.1001/jama.2013.278477. JAMA. 2013. PMID: 24108526 Clinical Trial.
For stroke volume index, the median AUC for esmolol was 4 mL/m2 (IQR, -1 to 10) vs 1 mL/m2 for the control group (IQR, -3 to 5; P = .02), whereas the left ventricular stroke work index for esmolol was 3 mL/m2 (IQR, 0 to 8) vs 1 mL/m2 for the control group (IQR, -2 t …
For stroke volume index, the median AUC for esmolol was 4 mL/m2 (IQR, -1 to 10) vs 1 mL/m2 for the control group (IQR, -3 to 5; P = . …
Esmolol, Antinociception, and Its Potential Opioid-Sparing Role in Routine Anesthesia Care.
Bahr MP, Williams BA. Bahr MP, et al. Reg Anesth Pain Med. 2018 Nov;43(8):815-818. doi: 10.1097/AAP.0000000000000873. Reg Anesth Pain Med. 2018. PMID: 30216240 Review.
Esmolol, to date, has not shown any direct analgesic or anesthetic properties; however, recent studies suggest that esmolol may have antinociceptive and postoperative opioid-sparing effects. In this Daring Discourse narrative, we describe the role of esmolol
Esmolol, to date, has not shown any direct analgesic or anesthetic properties; however, recent studies suggest that esmolol ma
Topical Esmolol Hydrochloride as a Novel Treatment Modality for Diabetic Foot Ulcers: A Phase 3 Randomized Clinical Trial.
Rastogi A, Kulkarni SA, Agarwal S, Akhtar M, Arsule S, Bhamre S, Bhosle D, Desai S, Deshmukh M, Giriraja KV, Jagannath J, Kashiva RY, Kesavan R, Khandelwal D, Kolte S, Kongara S, Darivemula AK, Madhusudan C, Pyare Saheb Qureshi MAH, Ramu M, Rathod G, Yalamanchi SR, Shakya S, Shetty P, Singh S, Deshpande SK, Viswanathan V, Unnikrishnan AG. Rastogi A, et al. JAMA Netw Open. 2023 May 1;6(5):e2311509. doi: 10.1001/jamanetworkopen.2023.11509. JAMA Netw Open. 2023. PMID: 37184839 Free article. Clinical Trial.
IMPORTANCE: Preclinical and phase 1/2 studies with esmolol hydrochloride suggest its potential role in treatment of diabetic foot ulcers (DFUs). ...The median time for ulcer closure was 85 days for the esmolol with SoC group and was not estimable for SoC only group. …
IMPORTANCE: Preclinical and phase 1/2 studies with esmolol hydrochloride suggest its potential role in treatment of diabetic foot ulc …
Basic pharmacology of esmolol.
Gorczynski RJ. Gorczynski RJ. Am J Cardiol. 1985 Oct 23;56(11):3F-13F. doi: 10.1016/0002-9149(85)90910-5. Am J Cardiol. 1985. PMID: 2864846 Review.
Preclinical studies show that esmolol is an ultrashortacting, cardioselective beta blocker that possesses minimal partial agonist action or membrane-depressant properties. The electrophysiologic and hemodynamic actions of esmolol are the result of beta blockade. No …
Preclinical studies show that esmolol is an ultrashortacting, cardioselective beta blocker that possesses minimal partial agonist act …
Effect of Esmolol on Clinical Outcomes in Critically Ill Patients: Data from the MIMIC-IV Database.
Liang Q, Li L, Chen K, An S, Deng Z, Li J, Zhou S, Chen Z, Zeng Z, An S. Liang Q, et al. J Cardiovasc Pharmacol Ther. 2023 Jan-Dec;28:10742484231185985. doi: 10.1177/10742484231185985. J Cardiovasc Pharmacol Ther. 2023. PMID: 37415421 Free article.
BACKGROUND AND AIMS: Esmolol is a common short-acting drug to control ventricular rate. ...Patients in esmolol group showed no significant difference in lactate levels and daily urine output when compared with those in non-esmolol group when adjusted for conf …
BACKGROUND AND AIMS: Esmolol is a common short-acting drug to control ventricular rate. ...Patients in esmolol group showed no …
Esmolol-digoxin drug interaction.
Lowenthal DT, Porter RS, Achari R, Turlapaty P, Laddu AR, Matier WL. Lowenthal DT, et al. J Clin Pharmacol. 1987 Aug;27(8):561-6. doi: 10.1002/j.1552-4604.1987.tb03067.x. J Clin Pharmacol. 1987. PMID: 2888792
Digoxin peak concentration and the time to reach the peak concentration were not affected by esmolol. However, the digoxin AUC during the six-hour esmolol infusion increased from 2.60 +/- 0.59 to 2.88 +/- 0.75 ng.hr/mL (P less than .05). ...The PR intervals were sim …
Digoxin peak concentration and the time to reach the peak concentration were not affected by esmolol. However, the digoxin AUC during …
Perioperative use of esmolol.
Reves JG, Flezzani P. Reves JG, et al. Am J Cardiol. 1985 Oct 23;56(11):57F-62F. doi: 10.1016/0002-9149(85)90917-8. Am J Cardiol. 1985. PMID: 2864850 Review.
With esmolol treatment, the difficulties of therapy with long-lasting beta blockers are avoided. ...Clinical studies performed during the perioperative period reveal that esmolol is safe and effective in this setting. Esmolol has been shown to be safe and eff …
With esmolol treatment, the difficulties of therapy with long-lasting beta blockers are avoided. ...Clinical studies performed during …
Esmolol hydrochloride: an ultrashort-acting, beta-adrenergic blocking agent.
Angaran DM, Schultz NJ, Tschida VH. Angaran DM, et al. Clin Pharm. 1986 Apr;5(4):288-303. Clin Pharm. 1986. PMID: 2871961 Review.
The chemistry, pharmacology, pharmacokinetics, hemodynamic and electrophysiologic effects, clinical efficacy, adverse effects, drug interactions, compatibility and stability, dosage, and administration of esmolol hydrochloride are reviewed. Esmolol produces c …
The chemistry, pharmacology, pharmacokinetics, hemodynamic and electrophysiologic effects, clinical efficacy, adverse effects, drug i …
971 results